Dosy
FAQSupport

GLP-1 Injection Site Rotation Guide

Proper injection site rotation prevents tissue damage, improves medication absorption, and reduces discomfort. Learn why it matters, where to inject, and how Dosy automates the process.

Why it matters

Why You Should Rotate Injection Sites

Injecting in the same spot repeatedly causes localized tissue changes that can affect both comfort and medication effectiveness:

Lipodystrophy prevention
Repeated injections in the same area can cause lipohypertrophy (fatty lumps) or lipoatrophy (tissue loss). These changes are cosmetically noticeable and can alter how medication is absorbed.
Consistent absorption
Scar tissue and fatty lumps from repeated injection at one site can slow or alter medication absorption, making blood levels less predictable. Rotation helps maintain consistent pharmacokinetics.
Reduced pain and bruising
Giving tissue time to heal between injections reduces tenderness, bruising, and the formation of hard spots at injection sites.
Clinical guidance
All GLP-1 RA manufacturer prescribing information recommends rotating injection sites. This is standard practice endorsed by the American Diabetes Association and other clinical bodies.
Where to inject

Approved Injection Sites for GLP-1 Medications

Per manufacturer labeling for injectable GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide, dulaglutide), the following subcutaneous injection sites are approved:

1
Abdomen
At least 2 inches from the navel. Avoid the waistline area. The abdomen typically provides the most consistent absorption.
2
Front of thigh
Middle third of the outer thigh. Avoid the knee area and inner thigh.
3
Upper arm
Back or outer area of the upper arm. May require assistance for self-injection at this site.
⚠️
Important: Always follow your prescribing provider's specific instructions regarding injection sites. Some areas may not be appropriate for all patients. Do not inject into areas with scars, bruises, redness, or hard lumps.
Dosy feature

Smart Rotation in Dosy Health

Dosy Smart Injection Site Rotation
Visual body map — See exactly where you last injected with a clear visual indicator. No more guessing or trying to remember.
Automatic rotation suggestions — Dosy suggests your next injection site based on your history, ensuring you don't repeat a site too soon.
Full injection history — Every injection is logged with its site, date, and dose. Review your rotation pattern over weeks or months.
Works with all injectables — Whether you're on semaglutide, tirzepatide, liraglutide, dulaglutide, or retatrutide — branded pens or compounded vials.

Rotation Best Practices

  • Move at least 1 inch (2.5 cm) from your previous injection site, even within the same body region.
  • Rotate between different body regions (abdomen → thigh → arm) on a consistent schedule.
  • Keep a log of where and when you inject. Memory alone is unreliable over weeks of treatment.
  • Inspect injection sites for lumps, dimples, or persistent redness — report these to your provider.
  • If you notice a site feels harder or medication seems less effective, rotate to a different region and inform your provider.

Medical Disclaimer

Dosy Health is an educational and tracking tool only. It does not provide medical advice, diagnosis, or treatment recommendations. All dosing decisions must be made by your healthcare provider.

Do not rely on any app, including Dosy, as a substitute for professional medical guidance. Always confirm your dose and injection instructions with your prescribing provider and pharmacist.

Dosy Health is not affiliated with, endorsed by, or associated with Novo Nordisk (manufacturer of Ozempic®, Wegovy®, Saxenda®, and Victoza®), Eli Lilly (manufacturer of Mounjaro®, Zepbound®, Trulicity®, and Foundayo®), or any compounding pharmacy.

Never Forget Where You Injected

Dosy's Smart Rotation tracks every injection site automatically.

Download on the App Store
Get it on Google PlaySoon

Sources

  1. Novo Nordisk. Ozempic® (semaglutide) Prescribing Information. Section 2.2: Administration Instructions.
  2. Eli Lilly. Mounjaro® (tirzepatide) Prescribing Information. Section 2.2: Administration Instructions.
  3. American Diabetes Association. "Insulin and Other Injectable Diabetes Medications." Standards of Care in Diabetes, 2024.
  4. Blanco M, et al. "Prevalence and risk factors of lipohypertrophy in insulin-injecting patients with diabetes." Diabetes & Metabolism, 2013.
  5. Frid AH, et al. "New Insulin Delivery Recommendations." Mayo Clinic Proceedings, 2016. DOI: 10.1016/j.mayocp.2016.06.010